Key Highlights
- JPMorgan upgraded LLY’s price objective to $1,400 from $1,300 while maintaining its Overweight stance
- RBC Capital pushed its target to an even more ambitious $1,500, holding its Outperform recommendation
- The bullish revisions reflect surging sales of obesity medications Mounjaro and Zepbound
- Medicare’s GLP-1 Bridge initiative, effective July 1, now offers Zepbound access for approximately $50 monthly
- Shares are currently trading around $1,235, reflecting a roughly 14% gain this year and approaching the 52-week peak of $1,249.45
On Tuesday, JPMorgan’s Chris Schott increased his Eli Lilly price objective to $1,400, up from his previous $1,300 mark, while reaffirming his Overweight recommendation. This revised forecast significantly exceeds the Street’s consensus estimate of approximately $1,305.
Coinciding with the upgrade announcement, LLY shares hit a new 52-week peak. Schott identified the pharmaceutical giant as his preferred healthcare sector investment.
RBC Capital simultaneously updated its outlook Tuesday, elevating its price target to $1,500 from $1,250 while keeping its Outperform designation intact. The firm noted that its internal revenue forecasts exceed consensus by approximately 1%, with Zepbound and Mounjaro performance tracking 5%-6% above market expectations.
Shares of LLY currently hover near $1,235, marking a roughly 7.5% increase over the past 30 days and approximately 14% growth since the year began. The stock’s 52-week floor stands at $623.78.
Schott forecasts second-quarter revenue of approximately $20.7 billion for Lilly, surpassing consensus estimates by roughly $300 million. He identified two primary catalysts: Mounjaro’s international market penetration and consistent U.S. demand for Zepbound.
During the first quarter of 2026, Lilly reported $19.8 billion in revenue, representing a robust 55.5% year-over-year increase. The Mounjaro and Zepbound franchises collectively generated approximately $12.8 billion in worldwide sales during that period. U.S. revenue climbed 43% to reach $12.1 billion, propelled by a 49% surge in prescription volume.
Following these impressive results, Lilly elevated its full-year 2026 revenue outlook to a range of $82 billion to $85 billion.
Medicare Access Program Unlocks Additional Revenue Potential
Beginning July 1, Medicare’s newly launched GLP-1 Bridge program extended access to Zepbound and the oral formulation Foundayo, making them available to qualifying patients for as little as $50 monthly. With an estimated 20 million Medicare beneficiaries potentially eligible, some market observers believe even the $1,400 price target may prove understated.
Broader affordability typically accelerates prescription growth, directly translating into the revenue metrics Wall Street monitors closely.
Increased demand volume has successfully counterbalanced the reduced pricing Lilly accepted in the U.S. marketplace, aligning precisely with management’s previous guidance to investors.
Robust Development Portfolio Strengthens Investment Thesis
Beyond its current blockbuster products, Schott emphasized Lilly’s development pipeline as an additional confidence driver. Notable experimental therapies include orforglipron, the oral GLP-1 now marketed as Foundayo, along with retatrutide, a triple-agonist compound currently undergoing clinical evaluation. Schott estimates the total addressable market for these therapeutic candidates exceeds $200 billion.
Competitive challenges faced by rival companies have further strengthened Lilly’s market position. Disappointing clinical trial outcomes from smaller competitors have solidified Lilly’s competitive advantages, creating what analysts characterize as substantial barriers to entry.
Lilly’s market capitalization currently approaches $1.16 trillion, with the stock trading at a price-to-earnings multiple near 44.
The next critical milestone arrives August 5, when Lilly unveils its second-quarter financial performance. RBC highlighted robust U.S. and international prescription volume growth, while anticipating pricing pressure in the low-to-mid-teen percentage territory.
Schott anticipates Q2 results may exceed expectations, though shares trading near historical peaks face elevated performance expectations from both bulls and bears.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
